Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease

International Immunology

Volumn 17, Issue 9, 2005, Pages 1179-1191

  Wang, Duncheng ^a   John, Shinu A ^a   Clements, James L ^b   Percy, Dean H ^c   Barton, Kevin P ^d   Garrett Sinha, Lee Ann ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GUELPH   (Canada)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

B cell activation; CpG oligodeoxynucleotide; Marginal zone; Pointed domain

Indexed keywords

CELL MARKER; CYTOSINE; GUANINE; OLIGONUCLEOTIDE; PHOSPHATE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR ETS 1;

ADOPTIVE TRANSFER; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE DIFFERENTIATION; CONTROLLED STUDY; DNA SEQUENCE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; GERMINAL CENTER; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; PLASMA CELLS; PROTO-ONCOGENE PROTEIN C-ETS-1; TOLL-LIKE RECEPTOR 9;

EID: 24144443497     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh295     Document Type: Article

References (54)

1. Reljic, R., Wagner, S. D., Peakman, L. J. and Fearon, D. T. 2000. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J. Exp. Med. 192:1841.
2. Lin, K. I., Angelin-Duclos, C., Kuo, T C. and Calame, K. 2002. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol. Cell. Biol. 22:4771.
3. Tunyaplin, C., Shaffer, A. L., Angelin-Duclos, C. D., Yu, X., Staudt, L. M. and Calame, K. L. 2004. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J. Immunol. 173:1158.
4. Lin, L., Gerth, A. J. and Peng, S. L. 2004. Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J. Exp. Med. 200:115.
5. Bories, J. C., Willerford, D. M., Grevin, D. et al. 1995. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature 377:635.
6. Muthusamy, N., Barton, K. and Leiden, J. M. 1995. Defective activation and survival of T cells lacking the Ets-1 transcription factor. Nature 377:639.
7. Barton, K., Muthusamy, N., Fischer, C. et al. 1998. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 9:555.
8. Eyquem, S., Chemin, K., Fasseu, M. et al. 2004. The development of early and mature B cells is impaired in mice deficient for the Ets-1 transcription factor. Eur. J. Immunol. 34:3187.
9. Seidel, J. J. and Graves, B. J. 2002. An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors. Genes Dev. 16:127.
10. Yang, B. S., Hauser, C. A., Henkel, G. et al. 1996. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16:538.
11. Foulds, C. E., Nelson, M. L., Blaszczak, A. G. and Graves, B. J. 2004. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol. Cell. Biol. 24:10954.
12. Maroulakou, I. G., Papas, T. S. and Green, J. E. 1994. Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis. Oncogene 9:1551.
13. Kola, I., Brookes, S., Green, A. R. et al. 1993. The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc. Natl Acad. Sci. USA 90:7588.
14. Walunas, T. L., Wang, B., Wang, C. R. and Leiden, J. M. 2000. Cutting edge: The Ets1 transcription factor is required for the development of NK T cells in mice. J. Immunol. 164:2857.
15. Eyquem, S., Chemin, K., Fasseu, M. and Bories, J. C. 2004. The Ets-1 transcription factor is required for complete pre-T cell receptor function and allelic exclusion at the T cell receptor {beta} locus. Proc. Natl Acad. Sci. USA 101:15712.
16. Vollmer, J., Weeratna, R. D., Jurk, M. et al. 2004. Oligodeoxynucleotides lacking CpG dinucleotices mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 113:212.
17. Pognonec, P., Boulukos, K. E., Bosselut, R., Boyer, C., Schmitt-Verhulst, A. M. and Ghysdael, J. 1990. Identification of a Ets1 variant protein unaffected in its chromatin and in vitro DNA binding capacities by T cell antigen receptor triggering and intracellular calcium rises. Oncogene 5:603.
18. Koizumi, S., Fisher, R. J., Fujiwara, S. et al. 1990. Isoforms of the human ets-1 protein: Generation by alternative splicing and differential phosphorylation. Oncogene 5:675.
19. Dierks, S. E., Campbell, K. A., Studer, E. J. and Conrad, D. H. 1994. Molecular mechanisms of murine Fc epsilon RII/CD23 regulation. Mol. Immunol. 31:1181.
20. Maliszewski, C. R., Grabstein, K., Fanslow, W. C., Armitage, R., Spriggs, M. K. and Sato, T. A. 1993. Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: Cooperative effects of cytokines. Eur. J. Immunol. 23:1044.
21. Hacker, H., Mischak, H., Miethke, T. et al. 1998. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:6230.
22. Yi, A. K. and Krieg, A. M. 1998. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J. Immunol. 161:4493.
23. Wasylyk, C., Bradford, A. P., Gutierrez-Hartmann, A. and Wasylyk, B. 1997. Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene 14:899.
24. Hibbs, M. L., Tarlinton, D. M., Armes, J. et al. 1995. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83:301.
25. Nishizumi, H., Taniuchi, I., Yamanashi, Y. et al. 1995. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 3:549.
26. Wang, J. H., Avitahl, N., Cariappa, A. et al. 1998. Aiolos regulates B cell activation and maturation to effector state. Immunity 9:543.
27. Sun, J., Matthias, G., Mihatsch, M. J., Georgopoulos, K. and Matthias, P. 2003. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J. Immunol. 170:1699.
28. Oliver, A. M., Martin, F., Gartland, G. L., Carter, R. H. and Kearney, J. F. 1997. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur. J. Immunol. 27:2366.
29. Oliver, A. M., Martin, F. and Kearney, J. F. 1999. IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J. Immunol. 162:7198.
30. Nelsen, B., Tian, G., Erman, B. et al. 1993. Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins. Science 261:82.
31. Goodnow, C. C., Crosbie, J., Adelstein, S. et al. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334:676.
32. Conrad, D. H., Waldschmidt, T. J., Lee, W. T. et al. 1987. Effect of B cell stimulatory factor-1 (interleukin 4) on Fc epsilon and Fc gamma receptor expression on murine B lymphocytes and B cell lines. J. Immunol. 139:2290.
33. Hasbold, J., Johnson-Leger, C., Atkins, C. J., Clark, E. A. and Klaus, G. G. 1994. Properties of mouse CD40: Cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 24:1835.
34. Roy, M., Aruffo, A., Ledbetter, J., Linsley, P., Kehry, M. and Noelle, R. 1995. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:596.
35. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. and Hodes, R. J. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
36. Stack, R. M., Lenschow, D. J., Gray, G. S., Bluestone, J. A. and Fitch, F. W. 1994. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J. Immunol. 152:5723.
37. Noelle, R. J., Kuziel, W. A., Maliszewski, C. R., McAdams, E., Vitetta, E. S. and Tucker, P. W. 1986. Regulation of the expression of multiple class II genes in murine B cells by B cell stimulatory factor-1 ( BSF-1). J. Immunol. 137:1718.
38. Noelle, R., Krammer, P. H., Ohara, J., Uhr, J. W. and Vitetta, E. S. 1984. Increased expression of Ia antigens on resting B cells: An additional role for B-cell growth factor. Proc. Natl Acad. Sci. USA 81:6149.
39. Li, X. and Qin, J. 2005. Modulation of Toll-interleukin 1 receptor mediated signaling. J. Mol. Med. 83:258.
40. Waldner, H., Collins, M. and Kuchroo, V. K. 2004. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113:990.
41. Anders, H. J., Vielhauer, V., Eis, V. et al. 2004. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 18:534.
42. Darabi, K., Karulin, A. Y., Boehm, B. O. et al. 2004. The third signal in T cell-mediated autoimmune disease? J. Immunol. 173:92.
43. Hasegawa, K. and Hayashi, T. 2003. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB × NZWF1 mice. Lupus 12:838.
44. Segal, B. M., Chang, J. T. and Shevach, E. M. 2000. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164:5683.
45. Tsunoda, I., Tolley, N. D., Theil, D. J., Whitton, J. L., Kobayashi, H. and Fujinami, R. S. 1999. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol. 9:481.
46. Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T. and Luster, A. D. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115:407.
47. Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J. and Marshak-Rothstein, A. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603.
48. Viglianti, G. A., Lau, C. M., Hanley, T. M., Miko, B. A., Shlomchik, M. J. and Marshak-Rothstein, A. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity 19:837.
49. Shultz, L. D. and Green, M. C. 1976. Motheaten, an immunodeficient mutant of the mouse. II. Depressed immune competence and elevated serum immunoglobulins. J. Immunol. 116:936.
50. Andrews, B. S., Eisenberg, R. A., Theofilopoulos, A. N. et al. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198.
51. Strasser, A., Whittingham, S., Vaux, D. L. et al. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl Acad. Sci. USA 88:8661.
52. Bouillet, P., Metcalf, D., Huang, D. C. et al. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735.
53. Mackay, F., Woodcock, S. A., Lawton, P. et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697.
54. Khare, S. D., Sarosi, I., Xia, X. Z. et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl Acad. Sci. USA 97:3370.